Recent developments in the diagnosis and management of tuberculosis (Q28077124)

21 June 2017

2 references

23 March 2019

22 June 2019

Recent developments in the diagnosis and management of tuberculosis (English)

1 reference

multidrug-resistant tuberculosis

21 June 2017

0 references

2 references

23 March 2019

22 June 2019

pulmonary tuberculosis

2 references

23 March 2019

22 June 2019

8

0 references

Giorgia Sulis

1

Giorgia Sulis

1 reference

21 June 2017

Antonio Spanevello

6

0 references

Rosella Centis

Rosella Centis

Giovanni Battista Migliori

2

0 references

Giovanni Battista Migliori

9

0 references

Alimuddin Zumla

8

Alimuddin Zumla

1 reference

21 June 2017

Giovanni Sotgiu

3

1 reference

21 June 2017

Emanuele Pontali

5

1 reference

21 June 2017

Alberto Matteelli

7

1 reference

21 June 2017

Lia D'Ambrosio

4

1 reference

21 June 2017

language of work or name

1 reference

3 November 2016

3 references

NPJ primary care respiratory medicine

21 June 2017

23 March 2019

22 June 2019

3 references

21 June 2017

23 March 2019

22 June 2019

26

1 reference

21 June 2017

16078

1 reference

Creative Commons Attribution 4.0 International

21 June 2017

2 references

23 March 2019

on focus list of Wikimedia project

22 June 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

European union standards for tuberculosis care

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Treatment of latent tuberculosis infection in HIV infected persons

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Shifting to Sustainable Development Goals--Implications for Global Health

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

24 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Recommendations for treating children with drug-resistant tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Stopping tuberculosis: a biosocial model for sustainable development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

A Novel Solid Medium for Culturing Mycobacterium tuberculosis Isolates from Clinical Specimens

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Latent Mycobacterium tuberculosis infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Towards tuberculosis elimination: an action framework for low-incidence countries

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Defining the needs for next generation assays for tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Multidrug-resistant tuberculosis around the world: what progress has been made?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Individual and social vulnerabilities upon acquiring tuberculosis: a literature systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Tuberculosis elimination: theory and practice in Europe

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

HIV-1 and the immune response to TB.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Challenges to the global control of tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

PEPFAR support for the scaling up of collaborative TB/HIV activities

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Social determinants of tuberculosis in Europe: a prospective ecological study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Tuberculosis: cost of illness in Germany

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Tuberculosis and noncommunicable diseases: neglected links and missed opportunities.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Reflections on the white plague

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Childhood tuberculosis: A roadmap towards zero deaths.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

Scaling up intensified tuberculosis case finding in HIV clinics in Rwanda

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

The burden of TB-HIV in the EU: how much do we know? A survey of surveillance practices and results.

2 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Delivering TB/HIV services in Ghana: a comparative study of service delivery models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Measuring the degree of integrated tuberculosis and HIV service delivery in Cape Town, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

History of Tuberculosis and Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

WHO's new end TB strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

WHO's new Stop TB Strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Point-of-care breath test for biomarkers of active pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Classification of antituberculosis drugs: a new proposal based on the most recent evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Compassionate and optimum use of new tuberculosis drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Bedaquiline plus delamanid for XDR tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Compassionate and optimum use of new tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5093435

The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection

27 November 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPJPCRM.2016.78

21 January 2018

Identifiers

DOI

10.1038/NPJPCRM.2016.78

1 reference

Dimensions Publication ID

21 June 2017

0 references

1 reference

1 reference